Investment Analysts’ Recent Ratings Updates for Keros Therapeutics (KROS)

A number of research firms have changed their ratings and price targets for Keros Therapeutics (NASDAQ: KROS):

• 12/16/2024 – Keros Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $102.00 to $63.00. They now have an “outperform” rating on the stock.
• 12/16/2024 – Keros Therapeutics was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 12/13/2024 – Keros Therapeutics had its price target lowered by analysts at Scotiabank from $77.00 to $44.00. They now have a “sector outperform” rating on the stock.
• 12/13/2024 – Keros Therapeutics had its price target lowered by analysts at HC Wainwright from $100.00 to $47.00. They now have a “buy” rating on the stock.
• 12/12/2024 – Keros Therapeutics was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 12/12/2024 – Keros Therapeutics was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
• 12/12/2024 – Keros Therapeutics was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating.
• 12/11/2024 – Keros Therapeutics had its price target raised by analysts at Wells Fargo & Company from $88.00 to $111.00. They now have an “overweight” rating on the stock.
• 12/4/2024 – Keros Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $102.00 price target on the stock, up previously from $96.00.
• 11/22/2024 – Keros Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 11/7/2024 – Keros Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
• 11/7/2024 – Keros Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
• 11/5/2024 – Keros Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating on the stock.
• 11/4/2024 – Keros Therapeutics was upgraded by analysts at Wedbush to a “strong-buy” rating.
• 10/24/2024 – Keros Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.

Keros Therapeutics Trading Up 0.7 %

KROS traded up $0.11 on Friday, hitting $17.03. The company had a trading volume of 1,468,811 shares, compared to its average volume of 487,363. The company’s fifty day moving average price is $54.97 and its 200 day moving average price is $51.59. The firm has a market cap of $689.83 million, a P/E ratio of -3.27 and a beta of 1.20. Keros Therapeutics, Inc. has a 1 year low of $15.67 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.33) earnings per share. On average, analysts predict that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares during the last quarter. Alkeon Capital Management LLC raised its stake in Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in Keros Therapeutics by 112.3% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock worth $24,493,000 after acquiring an additional 223,155 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after purchasing an additional 199,245 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.